The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.

Side by side

Compound comparison

Check interactions →Open as saved/share list

9-ME-BC

Research chemical · Grade C

Goals
cognition
Evidence
—
Routes
oral
WADA
No
FDA
Not approved
Cancer caution
none
Typical dose
—
Half-life
—
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →

Adamax

Research chemical · Grade C

Goals
cognition
Evidence
0 RCT / 2 animal / 0 in vitro
Routes
injectable-sc, nasal
WADA
No
FDA
Not approved
Cancer caution
none
Typical dose
—
Half-life
—
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →

ARA-290

Research chemical · Grade C

Goals
healing, cognition, mitochondria
Evidence
2 RCT / 1 animal / 0 in vitro
Routes
injectable-sc
WADA
S2
FDA
Not approved
Cancer caution
hard-stop
Typical dose
—
Half-life
ARA-290 has a plasma half-life of approximately 20 minutes after subcutaneous injection
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →

Cerebrolysin

Research chemical · Grade B

Goals
cognition, healing
Evidence
14 RCT / 0 animal / 0 in vitro
Routes
injectable-sc, injectable-im
WADA
No
FDA
Not approved
Cancer caution
none
Typical dose
—
Half-life
—
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →